Literature DB >> 29515938

Suppressed without a Cause: A Case of Idiopathic Immune Deficiency.

Muhammad Talha Ayub1, Munnam S Jafar2, Muhammad Khalid3, Muhammad A Baig1, Benjamin Mba1.   

Abstract

We report a case of a 45-year-old male who presented with a headache, fever, vomiting, somnolence, and difficulty walking for 10 days. His cerebrospinal fluid studies revealed cryptococcal meningitis. Chest and abdominal computed tomography (CT) scans showed splenomegaly along with mediastinal, retroperitoneal and inguinal lymphadenopathy. CD4 count turned out to be 208 μL-1. Human immunodeficiency virus (HIV) testing, serum protein electrophoresis, serum light chains and quantitative immunoglobulins were non-diagnostic and CD4 lymphopenia was attributed to acute infection. However, a persistent CD4 lymphopenia was seen in subsequent outpatient testing, which prompted a detailed workup for secondary causes of immunodeficiency. Repeated lymph node biopsies with analytic cytometric immunophenotypic analysis were normal, as was the bone marrow biopsy with detailed immunophenotypic and cytogenetic studies. The patient was hence being treated as a case of idiopathic CD4 lymphocytopenia.

Entities:  

Keywords:  idiopathic; lymphopenia; meningitis

Year:  2018        PMID: 29515938      PMCID: PMC5832397          DOI: 10.7759/cureus.2009

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


Introduction

Immunodeficiency is an inability to mount a normal immune response against a specific antigen in the form of antibodies or sensitized T cells. It can be congenital or acquired. Idiopathic CD4 lymphocytopenia (ICL) is a condition defined as persistent CD4 lymphocyte depletion (absolute CD4 count <300 μL−1 or <20% of total lymphocytes on two separate occasions 1-3 months apart) in the absence of human immunodeficiency virus (HIV) or any defined immune-deficiency disease or therapy [1].

Case presentation

A 45-year-old male with no past medical history presented with an occipital headache for 10 days. It was associated with fever, chills, nausea, vomiting, slurred speech, somnolence and difficulty walking. He denied focal weakness, paresthesia, neck stiffness, visual changes, chest pain, shortness of breath, urinary and bowel incontinence. The patient was in a monogamous heterosexual relationship. He endorsed a history of social drinking but denied smoking or drug abuse. Medication history was unremarkable. The patient was afebrile with a heart rate of 88 bpm, RR 21/min, and BP 136/97 mmHg. Physical exam was unremarkable except for pallor and inguinal lymphadenopathy. Labs were significant for hypotonic hyponatremia and normal complete blood count (CBC). Computed tomography (CT) scan head without contrast showed ex vacuo dilatation of the left lateral ventricle (Figure 1).
Figure 1

Computed tomography (CT) scan head without contrast showing ex vacuo dilatation of left lateral ventricle.

Lumbar puncture was done and cerebrospinal fluid (CSF) analysis unveiled cryptococcal meningitis. Multifocal nodularities involving bilateral basal ganglia consistent with cryptococcomas, were present on magnetic resonance imaging (MRI), along with leptomeningeal enhancement and chronic lacunar infarcts. Induction chemotherapy was started with amphotericin and flucytosine. CT chest, abdomen and pelvis reported diffuse mediastinal, retroperitoneal, inguinal lymphadenopathy with splenomegaly. Immunodeficiency workup revealed a CD4 count of 208 μL−1. HIV testing, serum protein electrophoresis, serum light chains and quantitative immunoglobulins were non-diagnostic. CD4 lymphopenia was attributed to acute infection and the patient was sent to a nursing home for two weeks of IV amphotericin therapy. However, he had persistently low absolute CD4 count ranging between 161 and 213 μL−1 on outpatient follow-up. Three serial lymph node biopsies for etiological workup of CD4 lymphopenia were nonconclusive, revealing a normal analytic cytometric immunophenotypic analysis. A bone marrow biopsy with immunophenotypic and cytogenetic studies (including karyotype, BCR/ABL1, JAK2 V617F, exon 12 mutations, fluorescent in situ hybridization (FISH) for platelet-derived growth factor receptor (PDGRF) alpha, beta, and fibroblast growth factor receptor 1 (FGFR1)) was normal. IgH gene rearrangement studies showed a weak peak on B cell framework III on repeat assays, not strong enough to be termed as monoclonal. T cell receptor (TCR) gamma gene arrangement did not point towards a definite diagnosis. Moreover, a review of the sample by the National Institutes of Health (NIH) also proved to be inconclusive. The patient was hence labeled as a case of idiopathic CD4 lymphocytopenia. After management of acute meningitis, he was discharged on fluconazole and augmentin therapy. The patient had a stable CD4 count without features of any immunodeficiency-related illness on the subsequent outpatient visits but was lost to follow up after three months of initial presentation. Attempts to contact the patient were unsuccessful, however, emergency contact (friend) revealed that he returned to India and was hospitalized for rapidly progressive dyspnea and confusion. He later died of multiorgan failure after 15 days of MICU stay.

Discussion

ICL was first defined by the Center for Disease Control and Prevention (CDC) in 1992 as low CD4 cell count in the absence of HIV and other secondary causes of immunodeficiency. Idiopathic CD4 lymphopenia is a rare immunological disorder associated with the persistent low CD4 count. The mean age at diagnosis is 41 year with slight male predominance [1]. Diagnostic criteria for ICL include a CD4 count < 300 cells or <20% of the total lymphocyte count, in the absence of HIV infection and secondary evidence of immunodeficiency conditions associated with low CD4 count [1,2]. In contrast to HIV, there is a slow progressive decline in the CD4 count. The pathogenesis is not well defined, but proposed mechanisms include: defective T cell production and differentiation, early maturation arrest, increased apoptosis, defective production of interferon gamma and increase destruction of cells due to sequestration in spleen and lymph node. The diagnosis of ICL should be sought when an opportunistic infection is diagnosed in an otherwise healthy individual. ICL predominantly presents with opportunistic infections like cryptococcus, human papillomavirus (HPV), and non-tuberculous mycobacterial species, especially Mycobacterium avium complex (MAC) [2-5]. Patients are also more prone to Epstein-Barr virus (EBV) related B-cell and central nervous system lymphomas, primary pleural effusion and Kaposi’s sarcoma. Loss of immune tolerance increases vulnerability to autoimmune diseases like antiphospholipid antibody syndrome, autoimmune hemolytic anemia, ulcerative colitis, Grave's disease, vitiligo, autoimmune thyroiditis, Behçet's disease, and vasculitis [3]. In addition to the aforementioned, skin disorders such as psoriasis and central nervous system conditions like progressive multifocal leukoencephalopathy have also been reported in association with ICL [6,7]. ICL is a diagnosis of exclusion so secondary causes of lymphopenia must be excluded to arrive at the diagnosis. The most common secondary causes are viral and bacterial infections, chemotherapy and cytotoxic drugs, malignancy and autoimmune conditions (Table 1). Our patient had immunodeficiency defined illness, cryptococcal meningitis, in the absence of any secondary causes of immune suppression as evident by extensive workup.
Table 1

Conditions associated with low CD4 count.

Conditions associated with low CD4 levels
AutoimmuneSjögren diseaseSystemic lupus erythematosusKikuchi disease
DrugsCorticosteroidsChemotherapyCytotoxic immunosuppressants
Genetic syndromesXMEN (X-linked magnesium deficiency with Epstein-Barr virus infection and neoplasia)WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis)Unc119 mutation (uncoordinated 119)
Hematologic conditionsLymphomaMyelodysplastic syndromesAplastic anemia
InfectionsHIV-1 and HIV-2 (human immunodeficiency virus)Human T-cell lymphotropic viruses 1 and 2Mycobacterium tuberculosisEpstein-Barr virusCytomegalovirusHuman herpes virus 6Recalcitrant warts
VariousCommon variable immune deficiencySarcoidosisRadiation therapy
There is no consensus for diagnostic investigations of ICL but the workup should be dictated by the presenting opportunistic infection and generally should include CD4, CD8, natural killer, and B-cell subsets, immunoglobulin levels, HIV 1-2 serology and polymerase chain reaction (PCR), human T-lymphotropic viruses type I (HTLV-I) and type II (HTLV-II) testing, EBV PCR, cytomegalovirus (CMV) PCR, and an autoantibody panel. The diagnosis is especially challenging in the presence of autoimmune diseases, since lymphopenia can be secondary to autoimmunity and vice versa, with transient immunosuppressant therapy-induced lymphopenia further complicating matters [4]. Although no published guidelines for the management of ICL exist, it is logical to assume that primary and secondary prophylaxis and treatment of opportunistic infections should form the mainstay of therapy. Our patient was discharged on antifungal and gram-positive therapy and was in remission before he was lost to follow up. Prophylaxis strategies generally follow recommendations for HIV. Live vaccines are contraindicated and should be avoided. Interleukin 2, gamma interferon and hematopoietic cell transplantation have been successfully used to augment the CD4 count in ICL whereas interleukin 7 is currently being studied [3]. Interleukin 2 and gamma interferon-mediated increase in CD4 counts improved clinical response to opportunistic infections such as cryptococcal meningitis and non-tuberculous mycobacterial infections. A study done in December 2015 with interleukin 7 showed promising results [8,9]. In contrast to HIV, ICL patients have a good prognosis and the progressive decline in CD4 counts is slow. Based on prospective studies, close monitoring with CD4 counts every four months is suggested in stable patients, especially for the first three years of diagnosis as there is a risk of serious infections and a possibility of normalization of CD4 T-cell counts within three years [6]. Our patient had a poor prognosis and died within six months of diagnosis from multiorgan failure, emphasizing the importance of close follow-up for early detection of life-threatening infections. Appropriate screening tests for chronic HPV infection-related squamous cell carcinoma should be employed as well. Low CD8 count (<180/mm3) and the degree of CD4 T-cell activation (measured by HLA-DR expression) are associated with adverse outcome (opportunistic infection-related death) [3].

Conclusions

ICL is a rare idiopathic condition which should be suspected when an opportunistic infection is detected in an otherwise healthy individual, which was cryptococcal meningitis in our case. Patients are more prone to develop malignancies and autoimmune diseases. A thorough workup excluding immunologic, hematologic, rheumatologic, and infectious etiologies should be carried out to establish a diagnosis of ICL. Our patient had extensive workup to reach this diagnosis of exclusion. Prophylaxis and treatment of opportunistic infections, regular follow-up with CD4 count and augmentation of immunity with interleukin 2, hematopoietic cell transplantation, interferon gamma and interleukin 7 therapy form the mainstay of management.
  9 in total

Review 1.  Idiopathic CD4 Lymphopenia: Severe CD4 Lymphopenia in the Absence of Human Immunodeficiency Virus Infection.

Authors:  Ilan Asher; Keren Mahlab-Guri; Daniel Elbirt; Shira Ezalel-Rosenberg; Zev Sthoeger
Journal:  Isr Med Assoc J       Date:  2016-10       Impact factor: 0.892

2.  Treatment of idiopathic CD4 T lymphocytopenia with IL-2.

Authors:  C Cunningham-Rundles; H W Murray; J P Smith
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Progressive Multifocal Leukoencephalopathy Localized in the Cerebellum and Brainstem Associated with Idiopathic CD4(+) T Lymphocytopenia.

Authors:  Yuya Aotsuka; Akiyuki Uzawa; Kazutaka Nishimura; Kazuho Kojima; Mika Yamaguchi; Takahiro Makino; Kazuo Nakamichi; Masayuki Saijo; Satoshi Kuwabara
Journal:  Intern Med       Date:  2016-06-15       Impact factor: 1.271

4.  Idiopathic CD4 lymphocytopenia.

Authors:  Joel P Brooks; Gisoo Ghaffari
Journal:  Allergy Asthma Proc       Date:  2016-11       Impact factor: 2.587

5.  Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors.

Authors:  Dimitrios I Zonios; Judith Falloon; John E Bennett; Pamela A Shaw; Doreen Chaitt; Michael W Baseler; Joseph W Adelsberger; Julia A Metcalf; Michael A Polis; Stephen B Kovacs; Stephen J Kovacs; Joseph A Kovacs; Richard T Davey; H Clifford Lane; Henry Masur; Irini Sereti
Journal:  Blood       Date:  2008-05-02       Impact factor: 22.113

6.  Psoriasis associated with idiopathic CD4+ T-cell lymphopenia: a regulatory T-cell defect?

Authors:  B Baroudjian; M Viguier; M Battistella; N Beneton; C Pagès; G Gener; E Bégon; H Bachelez
Journal:  Br J Dermatol       Date:  2014-06-22       Impact factor: 9.302

7.  Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report.

Authors:  S M Holland; E M Eisenstein; D B Kuhns; M L Turner; T A Fleisher; W Strober; J I Gallin
Journal:  N Engl J Med       Date:  1994-05-12       Impact factor: 91.245

Review 8.  Idiopathic CD4 lymphocytopenia: a case of missing, wandering or ineffective T cells.

Authors:  Dimitrios Zonios; Virginia Sheikh; Irini Sereti
Journal:  Arthritis Res Ther       Date:  2012-08-31       Impact factor: 5.156

9.  Idiopathic CD4 Lymphocytopenia: Spectrum of opportunistic infections, malignancies, and autoimmune diseases.

Authors:  Dina S Ahmad; Mohammad Esmadi; William C Steinmann
Journal:  Avicenna J Med       Date:  2013-04
  9 in total
  1 in total

Review 1.  Disseminated cryptococcosis with varicella-zoster virus coinfection of idiopathic CD4 + T lymphocytopenia: a case report and literature review.

Authors:  Li Fang; Junli Zhang; Fangfang Lv
Journal:  Virol J       Date:  2022-03-05       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.